# Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

> **NCT06010862** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 36 (estimated)

## Conditions studied

- Gastric Cancer
- Colon Cancer
- Pancreas Cancer
- Esophagus Cancer
- Cholangiocarcinoma
- Lung Cancer
- Breast Cancer

## Interventions

- **BIOLOGICAL:** CEA CAR-T cells
- **BIOLOGICAL:** CEA CAR-T cells

## Key facts

- **NCT ID:** NCT06010862
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06010862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06010862, "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06010862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*